ATE309808T1 - Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten - Google Patents

Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten

Info

Publication number
ATE309808T1
ATE309808T1 AT99944997T AT99944997T ATE309808T1 AT E309808 T1 ATE309808 T1 AT E309808T1 AT 99944997 T AT99944997 T AT 99944997T AT 99944997 T AT99944997 T AT 99944997T AT E309808 T1 ATE309808 T1 AT E309808T1
Authority
AT
Austria
Prior art keywords
cells
antagonists
allogene
xenogenic
vivo treatment
Prior art date
Application number
AT99944997T
Other languages
English (en)
Inventor
Randolph J Noelle
Bruce R Blazar
Daniel A Vallera
Patricia A Taylor
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE309808T1 publication Critical patent/ATE309808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT99944997T 1998-07-30 1999-07-29 Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten ATE309808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12468398A 1998-07-30 1998-07-30
PCT/US1999/016686 WO2000006178A1 (en) 1998-07-30 1999-07-29 EX VIVO TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE309808T1 true ATE309808T1 (de) 2005-12-15

Family

ID=22416260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99944997T ATE309808T1 (de) 1998-07-30 1999-07-29 Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten

Country Status (14)

Country Link
US (2) US20020048579A1 (de)
EP (2) EP1100515B1 (de)
JP (1) JP4109828B2 (de)
KR (1) KR100711210B1 (de)
CN (1) CN1161129C (de)
AT (1) ATE309808T1 (de)
AU (1) AU764015C (de)
CA (1) CA2338773A1 (de)
DE (1) DE69928407T2 (de)
DK (1) DK1100515T3 (de)
ES (1) ES2252970T3 (de)
HU (1) HUP0103107A2 (de)
NO (1) NO20010488L (de)
WO (1) WO2000006178A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8776230B1 (en) 2001-10-02 2014-07-08 Mcafee, Inc. Master security policy server
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20050112122A1 (en) * 2003-09-02 2005-05-26 Greiner Dale L. Generation of hematopoietic chimerism and induction of central tolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物

Also Published As

Publication number Publication date
CN1161129C (zh) 2004-08-11
EP1100515A4 (de) 2003-04-02
EP1100515B1 (de) 2005-11-16
NO20010488L (no) 2001-03-27
EP1100515A1 (de) 2001-05-23
KR20010071078A (ko) 2001-07-28
KR100711210B1 (ko) 2007-04-24
DK1100515T3 (da) 2005-12-12
EP1637146A2 (de) 2006-03-22
US20020022020A1 (en) 2002-02-21
NO20010488D0 (no) 2001-01-29
DE69928407D1 (de) 2005-12-22
CN1319019A (zh) 2001-10-24
DE69928407T2 (de) 2006-08-03
ES2252970T3 (es) 2006-05-16
HUP0103107A2 (hu) 2001-11-28
JP4109828B2 (ja) 2008-07-02
WO2000006178A1 (en) 2000-02-10
JP2002521042A (ja) 2002-07-16
EP1637146A3 (de) 2008-02-20
AU5770399A (en) 2000-02-21
AU764015B2 (en) 2003-08-07
AU764015C (en) 2006-03-16
CA2338773A1 (en) 2000-02-10
US20020048579A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
DE3781786D1 (de) Prothese zum implantieren im hypodermgewebe des urogenitalbereichs.
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
ATE113607T1 (de) Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
ES2147754T3 (es) Inactivacion selectiva de celulas en sangre.
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ATE514771T1 (de) Haartransplantation
FR2765483B1 (fr) Medicament destine a traiter les dysfonctions erectiles
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
FI972004A0 (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
ATE139230T1 (de) 5-ht-selektive mittel
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
ATE309808T1 (de) Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
WO2002033053A3 (en) Method for enhancing primordial germ cell number
UA32660A (uk) Підкладка до дерматомів
ITMI932171A1 (it) Procedimento per l'estrazione di colori naturali mediante bentonite
IT8621585V0 (it) Dispositivo per la guida in orizzontale della slitta, nei cestelli ed elementi in genere estraibili dei mobili.
UA30445A (uk) Спосіб оцінки чутливості до імунотропних препаратів

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100515

Country of ref document: EP

REN Ceased due to non-payment of the annual fee